Neurological Sciences最新文献

{"title":"The clinical and neuroradiological features of hypertrophic olivary degeneration following brainstem stroke.","authors":"Ziqu Zhang, Wen Jian, Nan Li, Xin Gao, Lin Chen, Xiaowei Zhang, Dan Cai, Jianle He, Yaqiong Nie, Yaoyao Shen","doi":"10.1007/s10072-025-08057-2","DOIUrl":"https://doi.org/10.1007/s10072-025-08057-2","url":null,"abstract":"<p><strong>Objectives: </strong>Hypertrophic olivary degeneration (HOD), a rare type of trans-synaptic degeneration of the central nervous system (CNS) caused by disruption of the dentato-rubro-olivary pathway (DROP), is mainly described in the form of case reports. Our aim in this study is to summarize the clinical and imaging characteristics of patients with HOD following brainstem stroke.</p><p><strong>Methods: </strong>A retrospective analysis was performed for all patients who were selected from electronic case databases between October 2019 and January 2024 in the Jiangxi Provincial People's Hospital and the Xinyu People's Hospital. The clinical data of included patients were summarized by our experienced neurologists. Besides, we analyzed the anatomical pathways between primary lesions in the brainstem and subsequent HOD.</p><p><strong>Results: </strong>A total of 11 patients, including 2 females and 9 males, were included in this retrospective study. HOD associated clinical presentations consisted of Holmes tremor (HT) (n = 6), palatal tremor (PT) (n = 4), cerebellar ataxia (n = 4), and nystagmus (n = 4). On initial MRI, pontine and midbrain lesions were found in 10 and 1 patients, respectively. Upon follow-up neuroradiological evaluation, unilateral and bilateral HOD appeared in 6 and 5 cases, respectively. Isolated mesencephalic lesion might lead to bilateral HOD, which was due to the involvement of the decussation of the superior cerebellar peduncle (SCP).</p><p><strong>Conclusion: </strong>For HOD associated clinical presentations, HT and cerebellar ataxia were the commonest. Unilateral pontine lesions might give rise to both unilateral and bilateral HOD, whereas bilateral HOD caused by isolated mesencephalic lesion was extremely rare.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurology, epilepsy, peace and Africa: narrative report of a lasting partnership.","authors":"Massimo Leone, Pierre Somsè, Alessandro Padovani, Giuseppe Lauria Pinter, Giovanni Guidotti","doi":"10.1007/s10072-025-08056-3","DOIUrl":"https://doi.org/10.1007/s10072-025-08056-3","url":null,"abstract":"","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the phenotypic spectrum of DNM1-related disorders: novel GTPase domain variants and their diverse neurological outcomes.","authors":"Juan Liu, Jihong Hu, Yaqin Duan, Yaqiong Tan, Quwen Gao, Gefei Wu","doi":"10.1007/s10072-024-07974-y","DOIUrl":"https://doi.org/10.1007/s10072-024-07974-y","url":null,"abstract":"<p><strong>Background: </strong>Pathogenic DNM1 variants cause early-onset developmental and epileptic encephalopathy (DEE). The GTPase domain of the DNM1 protein has the most commonly affected sites.</p><p><strong>Aim: </strong>This study aimed to delineate additional patients with DNM1-related disorders harboring novel GTPase domain variants.</p><p><strong>Methods: </strong>Trio whole-exome sequencing was performed on three Chinese probands with suspected encephalopathy, and Sanger sequencing was used to confirm the variants. Detailed evaluations were used to assess clinical features. Variant plasmids were constructed in vitro and transfected into cells, and the expression of mutant proteins was evaluated using western blotting (WB).</p><p><strong>Results: </strong>Three de novo heterozygous DNM1 variants were detected in the GTPase domain, namely, NM_004408.4: c.112_120delinsAGCGGCCAC, (p.Gly38_Gln40delinsSerGlyHis), c.457G > A, (p.Glu153Lys), and c.193 A > C, (p.Thr65Pro) in Patients 1, 2, and 3, respectively. Patients 2 and 3 exhibited typical DEE phenotypes with early-onset refractory seizures, profound developmental impairment, intellectual disability, and abnormal electroencephalography findings. However, Patient 1 did not have seizures and her clinical symptoms were autism features, mild hearing loss, subtle changes in the brain, and developmental delays. WB indicated that the expression of plasmids carrying the p.Thr65Pro and p.Glu153Lys variants was not significantly different from that in the wild-type control group and that the expression of the p.Gly38_Gln40delinsSerGlyHis plasmid was elevated.</p><p><strong>Conclusions: </strong>This study expands the genetic and phenotypic spectrum of DNM1-associated disorders and reveals that de novo pathogenic variants in the GTPase domain can lead to divergent neurological outcomes ranging from infantile epileptic encephalopathy syndromes to predominant developmental delays without seizures.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Longitudinal Strain score predicts subclinical cardiac involvement of multiple sclerosis patients.","authors":"Fidel Demir, Mehmet Özbek, Mehmet Ata Akıl, Eşref Akıl","doi":"10.1007/s10072-025-08041-w","DOIUrl":"https://doi.org/10.1007/s10072-025-08041-w","url":null,"abstract":"<p><strong>Background: </strong>People with multiple sclerosis (MS) have a higher risk of cardiovascular disease than the general population, but the data are limited. Evaluation with strain echocardiography, a new echocardiographic method, can provide more objective data to evaluate global and segmental left ventricular systolic functions. Left ventricular Global Longitudinal Strain (GLS) may be useful in demonstrating subclinical myocardial dysfunction in MS, therefore we planned such a study. We aim to evaluate LV functions with GLS obtained with basal tissue doppler in people with MS.</p><p><strong>Material and methods: </strong>A comparison of the demographic laboratory and echocardiographic findings of the multiple sclerosis patients with strain echocardiography records registered in our hospital and the control group with similar age and gender was performed. 80 RRMS patients and 65 control group were compared. Those with another chronic disease, those who received exacerbation treatment within the last month, those outside the age range of 18-65, and other forms of progressive MS were excluded from the study.</p><p><strong>Results: </strong>GLS scores was significantly lower in the MS group(-17.05 ± 1.33 vs.18.99 ± 1.08, p < 0.001). The optimal GLS score predicted poor LV functional status in people with MS with high EDSS scores with cut-off value ≤ 17.10, sensitivity of 73%, specificity of 58% [AUC: 0.652 95% CI, (0.531-0.773), p = 0.023]. It was observed that as the EDSS score increased, that is, in the presence of worse clinical condition, the GLS score decreased (r = -0.245, p = 0.003).</p><p><strong>Conclusions: </strong>We think that strain echocardiography may be useful in demonstrating subclinical myocardial damage in people with MS. We found that as the EDSS score, that is, the severity of the disease, increases, the subclinical effect on cardiac functions increases.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pons metabolite alterations in narcolepsy type 1.","authors":"Micaela Mitolo, Fabio Pizza, David Neil Manners, Lucia Guidi, Annalena Venneri, Luca Morandi, Caterina Tonon, Giuseppe Plazzi, Raffaele Lodi","doi":"10.1007/s10072-025-08009-w","DOIUrl":"https://doi.org/10.1007/s10072-025-08009-w","url":null,"abstract":"<p><strong>Introduction: </strong>Narcolepsy type 1 (NT1) is a rare central sleep disorder characterized by a selective loss of hypocretin/orexin (hcrt)-producing neurons in the postero-lateral hypothalamus that project to widespread areas of the brain and brainstem. The aim of this study was to explore in a group of NT1 patients the metabolic alterations in the pons and their associations with disease features.</p><p><strong>Methods: </strong>Twenty-one NT1 patients (16 M) and twenty age-matched healthy controls (10 M) underwent a brain ¹H MRS on a 1.5 T GE Medical Systems scanner. Metabolite content of N-acetyl-aspartate (NAA), choline (Cho), and myo-inositol (mI) were estimated relative to creatine (Cr), using LCModel 6.3. Clinical data were also collected with validated questionnaires, polysomnography, the Multiple Sleep Latency Test (MSLT), Cerebrospinal fluid hypocretin-1 (CSF hcrt-1) concentration and genetic markers.</p><p><strong>Results: </strong>NT1 patients compared with healthy controls showed lower NAA/Cr ratio (p = 0.007) and NAA/mI ratio (p = 0.011) in the pons. The Epworth Sleepiness Scale score showed a significant negative correlation with NAA/Cr content (p = 0.023), MSLT sleep latency a negative correlation with the mI/Cr ratio (p = 0.008), and sleep onset REM periods a positive correlation with the mI/Cr ratio (p = 0.027). CSF hcrt-1 levels were positively correlated with the NAA/Cr ratio (p = 0.039) and negatively with the mI/Cr ratio (p = 0.045) and the Cho/Cr ratio (p = 0.026).</p><p><strong>Conclusion: </strong>The metabolic alterations found in the pons of NT1 patients using the MR Spectroscopy technique were associated with subjective and objective disease severity measures, highlighting the crucial role of this biomarker in the pathophysiology of the disease.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurologic features in hospitalized patients with COVID-19: a prospective cohort in a catalan hospital.","authors":"Oriol Barrachina-Esteve, A Anguita, A Reverter, J Espinosa, C Lafuente, M Rubio-Roy, M Crosas, C Vila-Sala, C Acero, M Navarro, D Cánovas, G Ribera, M Jodar, J Estela","doi":"10.1007/s10072-025-08031-y","DOIUrl":"https://doi.org/10.1007/s10072-025-08031-y","url":null,"abstract":"<p><strong>Objectives: </strong>To study the prevalence and timing of neurological manifestations, including cognitive involvement, in patients hospitalized for Coronavirus disease 2019 (COVID-19). To analyze the pathogenic mechanisms and any association they have with disease severity.</p><p><strong>Methods: </strong>Longitudinal cohort study with prospective follow-up of patients who required hospitalization. Patients under 65 who had no pre-existing cognitive impairment and did not require an ICU stay were evaluated 3 and 12 months after discharge using a battery of neuropsychological tests.</p><p><strong>Results: </strong>Of 205 patients hospitalized for COVID-19, 153 (74.6%) presented with neurological manifestations. The most frequent were myalgia (32.7%), headache (31.7%), dysgeusia (29.2%), and anosmia (24.9%). Patients with more severe illness at the time of hospitalization presented fewer neurological manifestations. Of the 62 patients who underwent neuropsychological examination 3 months after discharge, 22.6% had impaired attention, 19.4% impaired working memory, 16.1% impaired learning and retrieval, 9.7% impaired executive functions, and 8.2% impaired processing speed. Patients with anosmia also presented with more headache (OR 5.45; p < 0.001) and greater risk of working memory impairment (OR 5.87; p 0.03). At follow-up 12 months after hospital discharge, 14.3% of patients still showed impaired attention, 2.4% impaired working memory, 2.5% impaired executive functions, and 2.5% impaired processing speed.</p><p><strong>Discussion: </strong>Neurological manifestations are common in patients hospitalized for COVID-19 regardless of severity. The high prevalence of anosmia and its association with headache and working memory impairment at 3 months, suggest potential direct or indirect damage to the prefrontal cortex via invasion of the olfactory bulb by COVID-19.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early versus escalation treatment of tocilizumab in neuromyelitis optica spectrum disorder: a retrospective study.","authors":"Yuan Qi, Rongrong Liu, Yuexin Zhao, Linjie Zhang, Qiuxia Zhang, Limin Li, Chunsheng Yang, Li Yang, Wei Jiang","doi":"10.1007/s10072-025-08046-5","DOIUrl":"https://doi.org/10.1007/s10072-025-08046-5","url":null,"abstract":"<p><strong>Background: </strong>Tocilizumab is effective in neuromyelitis optica spectrum disorder (NMOSD). It remains unclear when to initiate or discontinue tocilizumab treatment. We aimed to compare the efficacy of early versus escalation tocilizumab treatment in patients with NMOSD.</p><p><strong>Methods: </strong>A retrospective study of 41 patients with NMOSD who received regular tocilizumab administration was conducted. The early tocilizumab group comprised patients who started tocilizumab after their first attack, while the escalation group included patients who initially received empirical disease-modifying drugs (DMDs) and later escalated to tocilizumab after relapses. Tocilizumab was administered at 8 mg/kg with routine infusions at 4-week intervals. The primary outcome was improvement in the extended disability status scale (EDSS) score at months 3, 6, and 12 during the follow-ups. An additional secondary outcome was annualised relapse rate (ARR).</p><p><strong>Results: </strong>The early tocilizumab treatment group showed reduced median EDSS scores at 3, 6 months, with no further reduction at 12 months. The escalation treatment group showed reduced EDSS score at 6 months, with no further reduction at 12 months. The Inter-group analysis showed the early tocilizumab treatment group had significantly lower EDSS scores at 3, 6, and 12 months compared to the escalation treatment group. The ARR was not different at 36 months. Additionally, no difference of ARR was observed in those who were transferred to low-dose rituximab.</p><p><strong>Conclusions: </strong>Early use of tocilizumab reduces the degree of disability compared to escalation treatment in NMOSD, with no much differences on relapse rate. Low-dose rituximab may be a feasible candidate switching from tocilizumab.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Customizing Parkinson's care: sustaining continuous levodopa therapy post-gastrectomy.","authors":"Jolanda Buonocore, Michele Ammendola, Roberto Romano, Maurizio Morelli, Antonio Gambardella","doi":"10.1007/s10072-025-08042-9","DOIUrl":"https://doi.org/10.1007/s10072-025-08042-9","url":null,"abstract":"","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143409533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Levodopa-synergistic CBT intervention improves Parkinson's disease with anxiety disorder by regulating the BDNF/PI3K/AKT pathway.","authors":"Niu Ji, Shujin Lu, Bingchao Xu, Xinying Guan, Zhenping Xian, Deqin Geng, Dianshuai Gao","doi":"10.1007/s10072-025-07988-0","DOIUrl":"https://doi.org/10.1007/s10072-025-07988-0","url":null,"abstract":"<p><strong>Background: </strong>Anxiety disorder is one of the most common and disabling neuropsychiatric syndromes in patients with Parkinson's disease (PD), seriously affecting the quality of life and prognosis of PD patients.</p><p><strong>Objective: </strong>The objective of this study was to analyze the risk factors for anxiety in PD patients and to evaluate the effectiveness of cognitive behavioral therapy (CBT) in treating PD with anxiety disorder (PDAD).</p><p><strong>Methods: </strong>Baseline data were recorded for 211 PD patients and 139 PDAD patients, and multi-factorial and independent risk factors for anxiety disorder in PD patients were analyzed. ​The 139 PDAD patients were divided into clinical testing (CMO) and CBT groups. Assessments were taken at baseline and after the end of the intervention. A 5-month follow-up survey was conducted after the intervention. The mouse PD model was induced by MPTP, and the anxiety state of mice was detected by rotarod test and open-field test. The expression of BDNF/PI3K/Akt protein in serum and mouse brain was detected by western blot.</p><p><strong>Results: </strong>PDAD patients had significantly higher HAMA scores than PD patients. PSQI, ESS, HAMD, SCOPA-AUT, UPDRS-III and Hoehn-Yahr were independent risk factors for anxiety disorder in PD patients. After the intervention, the psychological state, cognitive function and quality of life improved in both the CMO and CBT groups, with the CBT group showing better improvement Results from follow-up showed that the number and frequency of falls was lower in the CBT group than in the CMO group, and that patients were more satisfied with the CBT intervention than the CMO group. L-dopa treatment alleviated anxiety in PD mice. L-dopa treatment increased BDNF, p-PI3K, and p-Akt protein levels. Moreover, the combination of L-dopa and CBT enhanced the boosting effect of L-dopa on these proteins.</p><p><strong>Conclusion: </strong>CBT is an effective treatment for anxiety in patients with Parkinson's disease. Medications combined with CBT have been shown to be effective in improving depression, anxiety and quality of life in PDAD patients.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotypic diversity in NAXE mutations.","authors":"Ismail Solmaz, Dilek Yalnızoğlu, Ali Dursun, Kısmet Çıkı, Halil Tuna Akar, Rıza Köksal Özgül, Can Koşukçu, Abdullah Sezer, Deniz Çağdaş, Saliha Esenboğa, Begüm Özbek, Damla Aygün, Didem Yücel Yılmaz, Şafak Parlak, Rahşan Göçmen, Kader Karlı Oğuz, Banu Anlar","doi":"10.1007/s10072-025-08006-z","DOIUrl":"https://doi.org/10.1007/s10072-025-08006-z","url":null,"abstract":"<p><strong>Background/aim: </strong>NAD(P)HX epimerase (NAXE) gene mutations have been associated with early onset progressive encephalopathy. We present three patients with NAXE gene mutations and different initial manifestations.</p><p><strong>Cases: </strong>Patient(P)1 was a 30 month-old boy whose neurological regression started after an infection and progressed, ultimately leading to death one year later. His brain magnetic resonance imaging (MRI) findings were suggesting metabolic stroke. P2, nine year-old sister of P1, had mild developmental delay since birth, seizures after age 5 years and pellagra-like skin lesions. P3 was a 15 year old female presenting multifocal neurological signs progressing over months and leading to respiratory insufficiency. Her initial MRI was normal but inflammatory lesions appeared three months after the onset of symptoms. Laboratory investigations including biochemical, serological and metabolic tests, and brain biopsy were unrevealing. Clinical presentation of P1 and P3 initially suggested autoimmune neurological disease, but no response to immunotherapy was obtained. Two different types of variants c.641T > G; p.Ile214Ser and c.128 C > A, p.Ser43* were detected in NAXE in these patients' two unrelated families. All patients were given mitochondrial cocktail including niacin.</p><p><strong>Discussion: </strong>NAXE plays an important role in the electron donors for the mitochondrial respiratory chain. Mutations result in accumulation of toxic metabolites, disruption of energy production, and possibly cell death. P1-3 displayed different ages of onset, different clinical courses and MRI findings unreported previously, suggesting immune-mediated encephalitis and metabolic stroke in P1, and an inflammatory process in P3. NAXE mutations should be considered in progressive central nervous system symptoms.</p>","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}